Taxus Financial Statements From 2010 to 2024
| CRXMDelisted Stock | USD 0.0001 0.00 0.00% |
Check Taxus Cardium financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Taxus main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Taxus financial statements analysis is a perfect complement when working with Taxus Cardium Valuation or Volatility modules.
Taxus |
Taxus Cardium Pharmaceuticals Company Shares Owned By Insiders Analysis
Taxus Cardium's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Taxus Cardium Shares Owned By Insiders | 0.21 % |
Most of Taxus Cardium's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Taxus Cardium Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
CompetitionBased on the latest financial disclosure, 0.21% of Taxus Cardium Pharmaceuticals are shares owned by insiders. This is 98.62% lower than that of the Biotechnology sector and 98.52% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 97.92% higher than that of the company.
Taxus Cardium Pharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Taxus Cardium's current stock value. Our valuation model uses many indicators to compare Taxus Cardium value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Taxus Cardium competition to find correlations between indicators driving Taxus Cardium's intrinsic value. More Info.Taxus Cardium Pharmaceuticals is rated below average in return on asset category among related companies. It is rated below average in current valuation category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Taxus Cardium by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Taxus Cardium's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Taxus Cardium's earnings, one of the primary drivers of an investment's value.About Taxus Cardium Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Taxus Cardium income statement, its balance sheet, and the statement of cash flows. Taxus Cardium investors use historical funamental indicators, such as Taxus Cardium's revenue or net income, to determine how well the company is positioned to perform in the future. Although Taxus Cardium investors may use each financial statement separately, they are all related. The changes in Taxus Cardium's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Taxus Cardium's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Taxus Cardium Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Taxus Cardium. Please read more on our technical analysis and fundamental analysis pages.
Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California. Taxus Cardium operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.
Pair Trading with Taxus Cardium
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Taxus Cardium position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Taxus Cardium will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Taxus Cardium could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Taxus Cardium when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Taxus Cardium - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Taxus Cardium Pharmaceuticals to buy it.
The correlation of Taxus Cardium is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Taxus Cardium moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Taxus Cardium Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Taxus Cardium can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Taxus Pink Sheet
If you are still planning to invest in Taxus Cardium Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Taxus Cardium's history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |